5 Reasons To Be Bullish On Celsion Now ............. The

New Post Public Reply Private Reply Replies (0) Message Board
Doubloon

5 Reasons To Be Bullish On Celsion Now .............

The legendary Peter Lynch once said "Never invest in any idea you can't illustrate with a crayon." When it comes to biotechs, that's often a challenge as their fundamentals are often very complex with seemingly endless data to sort through, making explaining the strong points in a short, simple illustrative summary a difficult task. But I shall attempt to do exactly that with this article, which is somewhat similar to last biotech I covered , Horizon Pharma ( HZNP ).

(1) CATALYST

In January 2013, Celsion ( CLSN ) is expected to release the results of its "Phase III HEAT Study, a multinational, double-blind, placebo-controlled, pivotal study of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer"

According to a recent company press release , "The HEAT Study addresses a significant and growing global unmet medical need in oncology, primary liver cancer. With a positive outcome, ThermoDox® will become the most important 1st line therapy for patients with non-resectable disease," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "The positive implications of this study, for patients and their families, the healthcare community, our investors and employees, cannot be overestimated."

(2) GOVERNMENT SUPPORT

This phase 3 is so important, so big, that the FDA granted it Fast Track Designation and Orphan Drug Designation in both the U.S. and Europe and allowed it to skip from Phase 1 to Phase 3 trials. In addition to this phase 3 trial for liver cancer, "ThermoDox® is also being evaluated in two Phase II trials for patients with recurrent chest wall breast cancer and colorectal liver metastases"

(3) MONEY

The company ended last quarter with $24 million in cash, $5 million available on their credit line with no plans to raise money until positive data from the study is released in January 2013 which, if successful, it is expected that the results will put CLSN on the map and bust the doors wide open to strategic and financing options.

(4) MARKET

According to the Q3 2012 conference call transcript , other companies have spent hundreds of millions of dollars for ThermoDox's principle indication HCC, yet HCC remains a large and deadly cancer, the world's fifth largest cancer, with "incidence is approximately 28,000 in the United States, 40,000 cases in Europe and it's rapidly growing at 5% worldwide from a base of 750,000 new cases annual." Additionally, "The World Health Organization estimates that HCC will become the number one cancer worldwide by 2020 surpassing lung cancer."

(5) INSIDER BUYING

Always nice to see insiders putting their money where their mouths are. Again, to quote the great Peter Lynch, "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise." The following is a list of insiders who bought in the open market within the last 3 months according to SEC filings :

  • On November 14, 2012, a director of the company Robert W. Hooper bought 60,320 shares at an average price of $5.20.
  • On September 13, 2012, an officer of the company Michael H. Tardugno bought 25,000 shares at an average price of $5.03 - $5.04.
  • On September 13, 2012, an officer of the company Jeffrey Wayne Church bought 9,860 shares at an average price of $4.93.
  • On September 9, 2012, a director of the company Robert W. Hooper bought 49,000 shares at an average price of $4.92 - $4.97.
  • On August 28, 2012, a director of the company Robert W. Hooper bought 11,625 shares at an average price of $4.65.

These are simple 5 reasons to be bullish on CLSN.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 23

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 63

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading